{"analyses":[{"ciLowerLimit":"-3.13","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"11.48","groupDescription":"1-Year ITT-WT Population","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.2624","paramType":"Difference in Event Free Rate","paramValue":"4.18","statisticalMethod":"Z-test"},{"ciLowerLimit":"2.43","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"16.90","groupDescription":"2-Year ITT-WT Population","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0088","paramType":"Difference in Event Free Rate","paramValue":"9.67","statisticalMethod":"Z-test"},{"ciLowerLimit":"-0.65","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"21.77","groupDescription":"1-Year Teff-high WT Population","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0649","paramType":"Difference in Event Free Rate","paramValue":"10.56","statisticalMethod":"Z-test"},{"ciLowerLimit":"-4.15","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"18.69","groupDescription":"2-Year Teff-high WT Population","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.2120","paramType":"Difference in Event Free Rate","paramValue":"7.27","statisticalMethod":"Z-test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"60.29","upperLimit":"74.68","value":"67.48"},{"groupId":"OG001","lowerLimit":"48.32","upperLimit":"65.53","value":"56.92"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"72"}],"units":"Participants"}],"title":"1-Year Teff-high WT Population"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"38.36","upperLimit":"53.66","value":"46.01"},{"groupId":"OG001","lowerLimit":"30.26","upperLimit":"47.22","value":"38.74"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"49"}],"units":"Participants"}],"title":"2-Year Teff-high WT Population"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"59.02","upperLimit":"69.11","value":"64.06"},{"groupId":"OG001","lowerLimit":"54.61","upperLimit":"65.17","value":"59.89"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"197"}],"units":"Participants"}],"title":"1-Year ITT-WT Population"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"36.26","upperLimit":"46.64","value":"41.45"},{"groupId":"OG001","lowerLimit":"26.75","upperLimit":"36.82","value":"31.79"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"104"}],"units":"Participants"}],"title":"2-Year ITT-WT Population"}],"denoms":[{"counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"197"}],"units":"Participants"}],"description":"OS at 1- and 2-year landmark timepoints in Teff-high WT population and ITT-WT population.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.","id":"OG000","title":"Arm A (Atezolizumab+Paclitaxel+Carboplatin)"},{"description":"Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.","id":"OG001","title":"Arm C (Bevacizumab+Paclitaxel+Carboplatin)"}],"paramType":"NUMBER","populationDescription":"Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.","reportingStatus":"POSTED","timeFrame":"Baseline to 2 years or death, whichever occurs first.","title":"OS Rates at Years 1 and 2 in Arm A Versus Arm C","type":"SECONDARY","unitOfMeasure":"Percentage"}